Published in Toxicol Sci on August 19, 2007
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol (2009) 1.49
Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol (2012) 1.36
Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal (2009) 1.18
Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol (2009) 1.17
Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp Ther (2009) 1.14
Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev (2009) 1.12
Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci (2013) 1.07
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci (2010) 1.06
Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol Biosyst (2010) 1.04
Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics (2010) 1.01
Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther (2008) 0.99
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep (2016) 0.96
Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci (2008) 0.96
Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci (2008) 0.94
Factors affecting drug-induced liver injury: antithyroid drugs as instances. Clin Mol Hepatol (2014) 0.92
Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther (2009) 0.92
Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro. PLoS One (2016) 0.91
Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy Asthma Immunol Res (2015) 0.91
Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci (2010) 0.91
A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood) (2015) 0.91
Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci (2011) 0.89
Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J Pharmacol Exp Ther (2009) 0.89
Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction. Toxicol Sci (2013) 0.89
Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci (2009) 0.85
Consequences of alteration in leucine zipper sequence of melittin in its neutralization of lipopolysaccharide-induced proinflammatory response in macrophage cells and interaction with lipopolysaccharide. J Biol Chem (2011) 0.83
Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-κB activation and sensitizes toward TNFα-induced cytotoxicity. Arch Toxicol (2015) 0.82
Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice. Toxicol Appl Pharmacol (2012) 0.81
Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment. Antimicrob Agents Chemother (2016) 0.80
The role of the immune system in nevirapine-induced subclinical liver injury of a rat model. ISRN Pharm (2012) 0.80
Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity. J Pharm Sci (2016) 0.80
Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase. J Pharmacol Exp Ther (2014) 0.79
Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. J Pharmacol Exp Ther (2014) 0.78
Thymoquinone and curcumin attenuate gentamicin-induced renal oxidative stress, inflammation and apoptosis in rats. EXCLI J (2014) 0.77
Chitohexaose protects against acetaminophen-induced hepatotoxicity in mice. Cell Death Dis (2016) 0.77
Hypoxia sensitization of hepatocytes to neutrophil elastase-mediated cell death depends on MAPKs and HIF-1α. Am J Physiol Gastrointest Liver Physiol (2012) 0.76
Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry. Rheumatol Int (2012) 0.76
Roles of the hemostatic system and neutrophils in liver injury from co-exposure to amiodarone and lipopolysaccharide. Toxicol Sci (2013) 0.75
Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res (2017) 0.75
Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study. Toxicol Rep (2017) 0.75
Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology (2006) 3.53
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol (2008) 2.77
Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci (2006) 1.75
Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact (2004) 1.49
Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology (2007) 1.23
Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther (2003) 1.17
Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther (2005) 1.15
Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp Ther (2009) 1.14
Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure. Toxicol Sci (2003) 1.13
Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther (2005) 1.12
Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev (2009) 1.12
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci (2007) 1.09
Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther (2006) 1.07
Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther (2005) 1.06
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci (2010) 1.06
Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. Toxicol Sci (2002) 1.06
Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology (2004) 1.06
Inflammation and drug idiosyncrasy--is there a connection? J Pharmacol Exp Ther (2003) 1.05
Hypoxia, drug therapy and toxicity. Pharmacol Ther (2006) 1.04
Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther (2002) 1.01
Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A (2010) 1.01
Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther (2008) 0.99
Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Lett (2004) 0.97
Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci (2008) 0.96
Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro (2006) 0.94
Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci (2008) 0.94
Modes of cell death in rat liver after monocrotaline exposure. Toxicol Sci (2003) 0.94
Workshop overview: Hepatotoxicity assessment for botanical dietary supplements. Toxicol Sci (2004) 0.93
Animal models of idiosyncratic drug-induced liver injury--current status. Crit Rev Toxicol (2011) 0.93
Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther (2007) 0.93
Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers. J Pharmacol Exp Ther (2003) 0.93
Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther (2009) 0.92
p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine. J Pharmacol Exp Ther (2008) 0.92
Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci (2010) 0.91
Complement activation in acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther (2012) 0.91
The role of hypoxia-inducible factor-1α in acetaminophen hepatotoxicity. J Pharmacol Exp Ther (2011) 0.90
Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J Pharmacol Exp Ther (2009) 0.89
Pulmonary leukostasis and the inhibition of airway neutrophil recruitment are early events in the endotoxemic rat. Shock (2002) 0.89
Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci (2011) 0.89
Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction. Toxicol Sci (2013) 0.89
Anticoagulation and inhibition of nitric oxide synthase influence hepatic hypoxia after monocrotaline exposure. Toxicology (2006) 0.88
The role of Kupffer cells and TNF-alpha in monocrotaline and bacterial lipopolysaccharide-induced liver injury. Toxicol Sci (2003) 0.87
Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology (2010) 0.86
A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther (2010) 0.86
Acute exposure to ozone exacerbates acetaminophen-induced liver injury in mice. Toxicol Sci (2010) 0.85
Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci (2009) 0.85
Liver inflammation during monocrotaline hepatotoxicity. Toxicology (2003) 0.85
The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol Appl Pharmacol (2009) 0.85
Augmentation of aflatoxin B1 hepatotoxicity by endotoxin: involvement of endothelium and the coagulation system. Toxicol Sci (2003) 0.84
Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol Sci (2011) 0.83
Anticoagulants prevent monocrotaline-induced hepatic parenchymal cell injury but not endothelial cell injury in the rat. Toxicol Appl Pharmacol (2002) 0.82
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J Pharmacol Exp Ther (2006) 0.82
The coagulation system contributes to synergistic liver injury from exposure to monocrotaline and bacterial lipopolysaccharide. Toxicol Sci (2003) 0.81
Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury. J Pharmacol Exp Ther (2008) 0.81
Endothelial cell injury and coagulation system activation during synergistic hepatotoxicity from monocrotaline and bacterial lipopolysaccharide coexposure. Toxicol Sci (2003) 0.80
Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury. Toxicology (2011) 0.80